Lamivudine
- Generic Name
- Lamivudine
- Brand Names
- Cimduo, Combivir, Delstrigo, Dovato, Epivir, Epivir Hbv, Epzicom, Kivexa, Symfi, Triumeq, Trizivir, Zeffix, Lamivudine Teva Pharma B.V., Lamivudine Teva
- Drug Type
- Small Molecule
- Chemical Formula
- C8H11N3O3S
- CAS Number
- 134678-17-4
- Unique Ingredient Identifier
- 2T8Q726O95
- Background
A reverse transcriptase inhibitor and zalcitabine analog in which a sulfur atom replaces the 3' carbon of the pentose ring. It is used to treat Human Immunodeficiency Virus Type 1 (HIV-1) and hepatitis B (HBV).
- Indication
For the treatment of HIV infection and chronic hepatitis B (HBV).
- Associated Conditions
- Chronic Hepatitis B Infection, Human Immunodeficiency Virus (HIV) Infections, Human Immunodeficiency Virus Type 1 (HIV-1) Infection
- Associated Therapies
- -
ABT-378/Ritonavir in Combination With Reverse Transcriptase Inhibitors in Antiretroviral Naïve HIV-Infected Subjects
- Conditions
- Interventions
- First Posted Date
- 2001-08-31
- Last Posted Date
- 2008-04-03
- Lead Sponsor
- Abbott
- Target Recruit Count
- 100
- Registration Number
- NCT00004578
- Locations
- 🇺🇸
Northwestern University Medical School, Chicago, Illinois, United States
🇺🇸University of Colorado Health Sciences Center, Denver, Colorado, United States
🇺🇸Baylor College of Medicine, Houston, Texas, United States
A Comparison of Epivir Plus Crixivan Combined With Zerit or Retrovir in HIV-Infected Patients Who Have Never Taken Anti-HIV Drugs
- Conditions
- First Posted Date
- 2001-08-31
- Last Posted Date
- 2007-10-02
- Lead Sponsor
- Bristol-Myers Squibb
- Target Recruit Count
- 200
- Registration Number
- NCT00002369
- Locations
- 🇵🇷
San Juan AIDS Program, Santurce, Puerto Rico
🇺🇸Boston Univ Med Ctr Hosp / Evans - 556, Boston, Massachusetts, United States
🇺🇸HIV Clinical Research Ctr, Fort Lauderdale, Florida, United States
A Comparison of Two Anti-HIV Triple-Drug Combinations in HIV-Infected Patients
- Conditions
- First Posted Date
- 2001-08-31
- Last Posted Date
- 2007-10-02
- Lead Sponsor
- Bristol-Myers Squibb
- Target Recruit Count
- 200
- Registration Number
- NCT00002168
- Locations
- 🇺🇸
Univ of Nebraska, Omaha, Nebraska, United States
🇺🇸Anderson Clinical Research, Washington, District of Columbia, United States
🇵🇷Hosp Regional de Ponce - Area Vieja, Ponce, Puerto Rico
Effectiveness of Anti-HIV Therapy (HAART) in HIV-Infected Patients With Tuberculosis
- Conditions
- First Posted Date
- 2001-08-31
- Last Posted Date
- 2008-09-11
- Target Recruit Count
- 44
- Registration Number
- NCT00004736
- Locations
- 🇺🇸
Univ of California / San Diego Treatment Ctr, San Diego, California, United States
🇺🇸Univ of Southern California / LA County USC Med Ctr, Los Angeles, California, United States
🇺🇸Vanderbilt Univ Med Ctr, Nashville, Tennessee, United States
A Study of Three Anti-HIV Drug Combinations in Patients Who Have Taken Amprenavir
- Conditions
- First Posted Date
- 2001-08-31
- Last Posted Date
- 2021-11-04
- Target Recruit Count
- 94
- Registration Number
- NCT00001095
- Locations
- 🇺🇸
St Louis Regional Hosp / St Louis Regional Med Ctr, Saint Louis, Missouri, United States
🇺🇸Univ of North Carolina, Chapel Hill, North Carolina, United States
🇺🇸Univ of Southern California / LA County USC Med Ctr, Los Angeles, California, United States
The Effectiveness of Ritonavir Plus Zidovudine Plus Lamivudine in HIV-Infected Patients
- Conditions
- First Posted Date
- 2001-08-31
- Last Posted Date
- 2021-11-04
- Target Recruit Count
- 55
- Registration Number
- NCT00001075
- Locations
- 🇺🇸
University of Colorado Hospital CRS, Aurora, Colorado, United States
🇺🇸Rush Univ. Med. Ctr. ACTG CRS, Chicago, Illinois, United States
🇺🇸Case CRS, Cleveland, Ohio, United States
Fortovase (Saquinavir) Given With Low-Dose Ritonavir, Zidovudine, and Lamivudine to HIV-Positive Pregnant Women During and After Pregnancy and to Their Newborns
- Conditions
- First Posted Date
- 2001-08-31
- Last Posted Date
- 2021-10-29
- Target Recruit Count
- 24
- Registration Number
- NCT00000920
- Locations
- 🇺🇸
Columbia Presbyterian Med Ctr, New York, New York, United States
🇺🇸Univ of Colorado Health Sciences Ctr, Denver, Colorado, United States
🇺🇸Children's Hosp of Michigan, Detroit, Michigan, United States
A Phase II Open-Label Exploratory Study of Saquinavir + Zidovudine + Lamivudine in HIV Infected Patients
- Conditions
- First Posted Date
- 2001-08-31
- Last Posted Date
- 2005-06-24
- Lead Sponsor
- Hoffmann-La Roche
- Target Recruit Count
- 30
- Registration Number
- NCT00002190
- Locations
- 🇺🇸
Davies Med Ctr / c/o HIV Institute, San Francisco, California, United States
🇺🇸Columbia Presbyterian Med Ctr, New York, New York, United States
🇺🇸Pacific Oaks Med Group / Rsch & Scientific Investigation, Sherman Oaks, California, United States
Safety and Effectiveness of Four Anti-HIV Drug Combinations in HIV-Infected Children and Teens
- Conditions
- First Posted Date
- 2001-08-31
- Last Posted Date
- 2021-11-04
- Target Recruit Count
- 200
- Registration Number
- NCT00001091
- Locations
- 🇺🇸
Harbor - UCLA Med Ctr / UCLA School of Medicine, Los Angeles, California, United States
🇺🇸State Univ of New York at Stony Brook, Stony Brook, New York, United States
🇺🇸Children's Hosp of Philadelphia, Philadelphia, Pennsylvania, United States
A Study of Indinavir Sulfate Plus Zidovudine (AZT) Plus Lamivudine in HIV-Infected Patients Who Have Taken AZT for Six or More Months
- Conditions
- First Posted Date
- 2001-08-31
- Last Posted Date
- 2021-11-04
- Target Recruit Count
- 1750
- Registration Number
- NCT00000841
- Locations
- 🇺🇸
Univ of Southern California / LA County USC Med Ctr, Los Angeles, California, United States
🇺🇸UCLA CARE Ctr, Los Angeles, California, United States
🇺🇸Emory Univ, Atlanta, Georgia, United States
Drug Development Updates
Stay informed with timely notifications on clinical trials, regulatory changes, and research advancements related to this medication.